Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 6, 2007, Pages 849-857

  Lai, E ^a   De Lepeleire, I ^a   Crumley, T M ^a   Liu, F ^a   Wenning, L A ^a   Michiels, N ^a   Vets, E ^b   O'Neill, G ^c   Wagner, J A ^a   Gottesdiener, K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Stuivenberg General Hospital   (Belgium)

^c MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LAROPIPRANT; NICOTINIC ACID; PLACEBO; PROSTAGLANDIN D2 RECEPTOR 1; PROSTAGLANDIN D2 RECEPTOR 1 ANTAGONIST; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATTENUATION; CLINICAL TRIAL; COLD CLAMMY SKIN; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; IMAGING; LASER DOPPLER FLOWMETRY; MALE; PERFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BLOOD FLOW; SKIN TEMPERATURE; VASODILATATION;

ADOLESCENT; ADULT; ASPIRIN; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NIACIN; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; REGIONAL BLOOD FLOW; SKIN; VASODILATION; VASODILATOR AGENTS;

EID: 34249024864     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100180     Document Type: Article

References (47)

1. Stason, W.B. Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol. Am. Heart J. 119, 718-724 (1990).
2. Boden, W.E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am. J. Cardiol. 86, 19L-22L (2000).
3. Wilson, P.W., Abbott, R.D. & Castelli, W.P. High density lipoprotein cholesterol and mortality: the Framingham Heart Study. Arteriosclerosis 8, 737-741 (1988).
4. Carlson, L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258, 94-114 (2005).
5. Canner, P.L., Furberg, C.D. & McGovern, M.E. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol. 97, 477-479 (2006).
6. Capuzzi, D.M. et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am. J. Cardiol. 82, 74U-81U (1998).
7. Morgan, J.M., Capuzzi, D.M. & Guyton, J.R. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am. J. Cardiol. 82, 29U-34U (1998).
8. Knopp, R.H. et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 47, 1097-1104 (1998).
9. Goldberg, A.C. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am. J. Cardiol. 82, 35U-38U (1998).
10. Capuzzi, D.M. et al. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am. J. Cardiol. 91, 1304-1310 (2003).
11. Wolfe, M.L. et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am. J. Cardiol. 87, 476-479, A7 (2001).
12. Guyton, J.R. & Capuzzi, D.M. Treatment of hyperlipidemia with combined niacin-statin regimens. Am. J. Cardiol. 82, 82U-84U (1998).
13. McKenney, J.M. et al. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. Am. J. Med. 104, 137-143 (1998).
14. Davignon, J. et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am. J. Cardiol. 73, 339-345 (1994).
15. Brown, G. et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323, 1289-1298 (1990).
16. Blankenhorn, D.H. et al. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257, 3233-3240 (1987).
17. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231, 360-381 (1975).
18. Canner, P.L. et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8, 1245-1255 (1986).
19. Taylor, A.J., Sullenberger, L.E., Lee, H.J., Lee, J.K. & Grace, K.A. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110, 3512-3517 (2004).
20. Moon, Y.S. & Kashyap, M.L. Niacin extended-release/lovastatin: combination therapy for lipid disorders. Expert Opin. Pharmacother. 3, 1763-1771 (2002).
21. Crouse, J.R. III. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Coron. Artery Dis. 7, 321-326 (1996).
22. King, J.M. et al. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am. J. Med. 97, 323-331 (1994).
23. Capuzzi, D.M., Morgan, J.M., Brusco, O.A. Jr. & Intenzo, C.M. Niacin dosing: relationship to benefits and adverse effects. Curr. Atheroscler. Rep. 2, 64-71 (2000).
24. Mills, E. et al. The safety of over-the-counter niacin: a randomized placebo-controlled trial [ISRCTN18054903]. BMC. Clin. Pharmacol. 3, 4 (2003).
25. Kos Pharmaceuticals (Cranbury, NJ). Niaspan® (niacin extended-release tablets) US prescribing information. © 2005. Available at www.niaspan.com/pdf/niaspan_pi_r1.pdf. Accessed 22 March 2006.
26. McCormack, P.L. & Keating, G.M. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs 65, 2719-2740 (2005).
27. McKenney, J. Niacin for dyslipidemia: considerations in product selection. Am. J. Health Syst. Pharm. 60, 995-1005 (2003).
28. McKenney, J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med. 164, 697-705 (2004).
29. Pieper, J.A. Understanding niacin formulations. Am. J. Manag. Care 8, S308-S314 (2002).
30. Jungnickel, P.W., Maloley, P.A., Vander Tuin, E.L., Peddicord, T.E. & Campbell, J.R. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J. Gen. Intern. Med. 12, 591-596 (1997).
31. Whelan, A.M., Price, S.O., Fowler, S.F. & Hainer, B.L. The effect of aspirin on niacin-induced cutaneous reactions. J. Fam. Pract. 34, 165-168 (1992).
32. Wilkin, J.K. et al. Aspirin blocks nicotinic acid-induced flushing. Clin. Pharmacol. Ther. 31, 478-482 (1982).
33. Dunn, R.T., Ford, M.A., Rindone, J.P. & Kwiecinski, F.A. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am. J. Ther. 2, 478-480 (1995).
34. Svedmyr, N., Heggelund, A. & Aberg, G. Influence of indomethacin on flush induced by nicotinic acid in man. Acta. Pharmacol. Toxicol. (Copenh.) 41, 397-400 (1977).
35. Phillips, W.S. & Lightman, S.L. Is cutaneous flushing prostaglandin mediated? Lancet 1, 754-756 (1981).
36. Kaijser, L., Eklund, B., Olsson, A.G. & Carlson, L.A. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med. Biol. 57, 114-117 (1979).
37. Benyó, Z. et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J. Clin. Invest. 115, 3634-3640 (2005).
38. 2 in man. Prostaglandins 28, 755-767 (1984).
39. 2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38, 263-274 (1989).
40. Stern, R.H., Spence, J.D., Freeman, D.J. & Parbtani, A. Tolerance to nicotinic acid flushing. Clin. Pharmacol. Ther. 50, 66-70 (1991).
41. 2 release following oral administration of niacin in humans. J. Invest. Dermatol. 98, 812-815 (1992).
42. 2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98, 1942-1948 (2001).
43. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 193, 255-261 (2001).
44. 2 receptor and functional expression of the cloned gene. Proc. Natl. Acad. Sci. USA 91, 11192-11196 (1994).
45. 2 receptor one suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. USA 103, 6682-6687 (2006).
46. Berra, K. Clinical update on the use of niacin for the treatment of dyslipidemia. J. Am. Acad. Nurse Pract. 16, 526-534 (2004).
47. Fullerton, A. et al. Guidelines for visualization of cutaneous blood flow by laser Doppler perfusion imaging: a report from the Standardization Group of the European Society of Contact Dermatitis based upon the HIRELADO European community project. Contact Derm. 46, 129-140 (2002).